San Francisco, CANCT07199465Now EnrollingIRB Ready

Cytomegalovirus Prophylaxis Clinical Trial in San Francisco, CA

Access cutting-edge cytomegalovirus prophylaxis treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.

Sponsored by Merck Sharp & Dohme LLC

Quick Self-Assessment

See if you qualify for this San Francisco location

Preparing your pre-screening questions…

Expert Care in San Francisco

Access cytomegalovirus prophylaxis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related cytomegalovirus prophylaxis treatment provided free

Apply for This San Francisco Location

Check if you qualify for this cytomegalovirus prophylaxis clinical trial in San Francisco, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Francisco

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Francisco site if eligible
  4. 4Begin participation

About This Cytomegalovirus Prophylaxis Study in San Francisco

Researchers are looking for a way to prevent cytomegalovirus (CMV) in children and adolescents who receive a kidney transplant (KT) and weigh less than 40 kilograms (88.2 pounds). The goals of the study are to: * Learn what happens to letermovir in the body over time * Learn about the safety of letermovir and if participants tolerate it

Sponsor: Merck Sharp & Dohme LLC

Who Can Participate

Inclusion Criteria

The main inclusion criteria include but are not limited to the following:
Is a recipient of a primary or secondary allograft kidney
Is at least 4 weeks posttransplant and not more than 52 weeks posttransplant at the time of enrollment (Day 1) and is being managed per local standard of care
Has stable kidney function posttransplant
Has undetectable CMV deoxyribonucleic acid (DNA) from a plasma or whole blood sample collected within 14 days prior to enrollment
Must be able to take (as assessed by the investigator) letermovir tablets or oral pellets by mouth, or via gastrostomy or nasogastric tube (oral pellets only)
Does not have a condition that may interfere with the absorption of oral medication (e.g., vomiting, diarrhea, or a malabsorptive condition) from the day of enrollment (Day 1) until the intensive pharmacokinetics (IPK) sampling is completed
Weighs ≥2.5 and \<40 kg at enrollment (Day 1)

Exclusion Criteria

The main exclusion criteria include but are not limited to the following:
Has CMV disease or suspected CMV disease between screening and enrollment
Is on dialysis or plasmapheresis at the time of enrollment
Has evidence of CMV viremia at any time from screening until the time of enrollment
Has Child-Pugh B or C hepatic insufficiency within 14 days before enrollment
Is a multi-organ transplant recipient (e.g., kidney-pancreas)
Has any uncontrolled infection on the day of enrollment
Requires mechanical ventilation, or is hemodynamically unstable, at the time of enrollment
Has received or is receiving protocol-specified prohibited medications

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Francisco?

Yes, this clinical trial (NCT07199465) has an active research site in San Francisco, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Cytomegalovirus Prophylaxis Treatment Options in San Francisco, CA

If you're searching for cytomegalovirus prophylaxis treatment options in San Francisco, CA, this clinical trial (NCT07199465) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced cytomegalovirus prophylaxis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all cytomegalovirus prophylaxis clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Hypertension Trials in San Francisco, CA

See all pulmonary hypertension clinical trials recruiting in San Francisco — not just this study.

Browse Pulmonary Hypertension Trials in San Francisco →

Browse More Trials by Condition

Pulmonary Hypertension TrialsGeographic Atrophy TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in San Francisco?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Francisco, CA